Skip to content

Author

R. Loutati

We have 13 of 16 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Frailty redefines the prognostic value of multimorbidity in heart failure

Multimorbidity is common and associated with adverse outcomes in heart failure (HF). However, its prognostic value across frailty states is uncertain, particularly whether comorbidities continue to stratify risk once frailty develops. To evaluate whether frailty modifies the association of multimorbidity i...

V. Copeland, B. Fishman, S. Elimelech et al. · 0 citations
Open access Oct 2026

Frailty across the lifespan in heart failure: age-modified drivers and prognostic implications

Frailty is a multidimensional syndrome of reduced physiologic reserve associated with adverse outcomes in heart failure (HF). Whether its underlying drivers and prognostic significance differ by age remains poorly understood. To assess age-specific correlations of frailty, predictors of incident frailty, a...

V. Copeland, B. Fishman, S. Elimelech et al. · 0 citations
Open access Oct 2026

AI-derived cardiovascular age from point-of-care ultrasound uncovers accelerated cardiometabolic aging

AI-derived CV biological age from FoCUS identifies subclinical cardiometabolic vulnerability independent of chronological age in asymptomatic adults, and may enhance personalized risk profiling and guide early preventive interventions in asymptomatic adults.

R. Amster, D. Simanovsky, R. Loutati et al. · 0 citations
Review Open access Oct 2026

Prognostic power of artificial intelligence based estimation of left ventricular ejection fraction in standard and point-of-care echocardiography

Artificial intelligence (AI)-based left ventricular ejection fraction (LVEF) estimation compares reasonably well with conventional readings. We assessed its prognostic value in the standard transthoracic echocardiography (TTE) and point-of-care-ultrasound (POCUS) settings. AI-based LVEF estimation was retr...

K. Faierstein, R. Loutati, M. Fiman et al. · 0 citations
Open access Oct 2026

Grading left ventricular diastolic function and filling pressure using artificial intelligence-enabled echocardiography

Assessment of left ventricular diastolic dysfunction (LVDD) and filling pressure is standard in echocardiography but remains time- and expertise-dependent. We evaluated the performance and prognostic significance of an artificial intelligence (AI)-enabled echocardiography for LVDD grading. An AI model was...

R. Loutati, M. Fiman, A. Amshalom et al. · 0 citations
Open access Oct 2026

Sex-specific impact of chronic kidney disease on mortality and dialysis in heart failure with metabolic syndrome

Cardiovascular-kidney-metabolic (CKM) syndrome is a systemic disorder defined by the overlapping burden of heart failure (HF), chronic kidney disease (CKD), diabetes, and obesity. Although sex differences in cardiovascular disease are increasingly recognized, sex-specific patterns of mortality and renal progressi...

D. Hochstein, R. Loutati, V. Copeland et al. · 0 citations
Open access Sep 2026

Real-world safety of concomitant colchicine and statin therapy.

OBJECTIVE This study aimed to evaluate the risk of clinically meaningful muscle- and liver-related outcomes associated with concomitant colchicine-statin therapy in a real-world setting, and to determine whether concomitant therapy increases the incidence of toxicity compared with either agent alone. METHODS A retros...

R. Meidan, R. Loutati, D. Caspi et al. · 0 citations
Open access Oct 2026

Improving outcomes in HFpEF with advanced CKD: temporal trends from the SHEBAHEART Registry

Patients with advanced chronic kidney disease (CKD) and heart failure (HF) are systematically underrepresented in clinical trials despite comprising a substantial proportion of real-world HF populations [1]. Whether contemporary care has translated into improved outcomes in this high-risk group particularly among...

D. Hochstein, D. Sternik, V. Copeland et al. · 0 citations
Open access Oct 2026

Adverse effect of left ventricular hypertrophy in women with heart failure

Left ventricular hypertrophy is a hallmark of adverse remodeling in heart failure (HF), yet commonly used echocardiographic measures provide limited insight into sex-specific risk. Interventricular septal (IVS) thickness is routinely measured, but its independent prognostic value and potential sex-related differe...

A. Kaplan, V. Copeland, R. Loutati et al. · 0 citations
Open access Oct 2026

Chronic kidney disease in metabolic syndrome and heart failure: elevated risk, underutilized therapies, and missed opportunities for improved outcomes

In patients with late-stage metabolic syndrome, CKD identifies a high-risk subgroup with a graded increase in mortality and dialysis risk compared with eGFR ≥60, and the heightened dialysis risk remained pronounced after accounting for competing death.

D. Hochstein, R. Loutati, V. Copeland et al. · 0 citations
Sep 2026

Calcium Channel Blockers are Safe and Beneficial in Patients with Heart Failure and Advanced Chronic Kidney Disease.

In patients with heart failure and advanced chronic kidney disease, CCBs use was associated with improved survival, supporting their potential role as a safe adjunctive therapy for blood pressure control in this high-risk population.

V. Copeland, A. Milwidsky, S. Elimeleh et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.